Achillion Pharmaceuticals (ACHN) 9.76 $ACHN
Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.
New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo
PR Newswire - Wed Aug 20, 7:40AM CDT
Today, Analysts Review released its research reports regarding Covidien PLC (NYSE: COV), Mylan, Inc. (NASDAQ: MYL), Baxter International Inc. (NYSE: BAX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Perrigo Company PLC (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5849-100free.
ACHILLION PHARMA
at Investor's Business Daily - Tue Aug 19, 5:47PM CDT
ACHILLION PHARMA (ACHN) got a patent OK for ACH-3102, its hepatitis C treatment. Shares rose 2.8% after closing up 3.5%.
Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today
at The Street - Tue Aug 19, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) rose in after-hours trading Tuesday after the company received a patent for its hepatitis C drug ACH-3102.
Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors
GlobeNewswire - Tue Aug 19, 3:05PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation Phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.
Can The Uptrend Continue for Achillion (ACHN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 6:57AM CDT
Can The Uptrend Continue for Achillion (ACHN)?
Achillion Pharmaceuticals
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
Achillion Pharmaceuticals (ACHN) was upgraded to buy from hold by Deutsche Bank, and its price target was raised to 17 from 6 on good news about its new hepatitis drug. Shares rose 3.1% to 9.5.
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.
Should Achillion Pharma (ACHN) Be In Your Portfolio Now? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 18, 2:20PM CDT
ACHN is soaring today, but have investors already missed all the big gains?
Achillion Pharmaceuticals Up On Buyout Rumors
at Investor's Business Daily - Mon Aug 18, 12:52PM CDT
Achillion Pharmaceuticals (ACHN) stock touched an 18-month high for the second straight trading day on Monday, after Deutsche Bank upgraded the biotech startup and boosted price target on positive news about its new hepatitis drug. Achillion stock...
3 Big Stocks on Traders' Radars
at The Street - Mon Aug 18, 11:02AM CDT
Here's how to trade some of the most active stocks on the market today.
Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
at The Street - Mon Aug 18, 9:12AM CDT
Achillion Pharmaceuticals (ACHN) hit a 52-week high of $10.10 on Monday after Deutsche upgraded the stock and increased its price target 183%.
Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.
Nasdaq stocks posting largest percentage increases
AP - Fri Aug 15, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod
at Investor's Business Daily - Fri Aug 15, 4:44PM CDT
Big-cap biotech Gilead Sciences (GILD) rose 3.2% to 99.49 on the stock market today, hitting a new all-time high Friday after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.'s...
Why Achillion Pharmaceuticals, Inc. Stock Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 15, 1:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Achillion Pharmaceuticals , a...
Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead Sciences, Amgen, Roche and Biogen
PR Newswire - Thu Aug 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Biotechnology Stocks to Keep an Eye On
ACCESSWIRE - Wed Aug 20, 8:01AM CDT
Deerfield Beach, FL / Aug 20, 2014 / It has been a disappointing year for biotechnology stocks so far after last year's surge. The correction was expected after last year's surge; however, the losses were accentuated after Fed Chair Janet Yellen's comments earlier this year regarding a possible bubble in biotech and social media stocks.
New Drug Launches, Technical Updates, New Facility, Clinical Trials Data, and Dividend Declarations - Research Reports on Covidien, Mylan, Baxter, Achillion and Perrigo
PR Newswire - Wed Aug 20, 7:40AM CDT
Today, Analysts Review released its research reports regarding Covidien PLC (NYSE: COV), Mylan, Inc. (NASDAQ: MYL), Baxter International Inc. (NYSE: BAX), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Perrigo Company PLC (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5849-100free.
ACHILLION PHARMA
at Investor's Business Daily - Tue Aug 19, 5:47PM CDT
ACHILLION PHARMA (ACHN) got a patent OK for ACH-3102, its hepatitis C treatment. Shares rose 2.8% after closing up 3.5%.
Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today
at The Street - Tue Aug 19, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) rose in after-hours trading Tuesday after the company received a patent for its hepatitis C drug ACH-3102.
Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors
GlobeNewswire - Tue Aug 19, 3:05PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation Phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.
Can The Uptrend Continue for Achillion (ACHN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 6:57AM CDT
Can The Uptrend Continue for Achillion (ACHN)?
Achillion Pharmaceuticals
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
Achillion Pharmaceuticals (ACHN) was upgraded to buy from hold by Deutsche Bank, and its price target was raised to 17 from 6 on good news about its new hepatitis drug. Shares rose 3.1% to 9.5.
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.
Should Achillion Pharma (ACHN) Be In Your Portfolio Now? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 18, 2:20PM CDT
ACHN is soaring today, but have investors already missed all the big gains?
Achillion Pharmaceuticals Up On Buyout Rumors
at Investor's Business Daily - Mon Aug 18, 12:52PM CDT
Achillion Pharmaceuticals (ACHN) stock touched an 18-month high for the second straight trading day on Monday, after Deutsche Bank upgraded the biotech startup and boosted price target on positive news about its new hepatitis drug. Achillion stock...
3 Big Stocks on Traders' Radars
at The Street - Mon Aug 18, 11:02AM CDT
Here's how to trade some of the most active stocks on the market today.
Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
at The Street - Mon Aug 18, 9:12AM CDT
Achillion Pharmaceuticals (ACHN) hit a 52-week high of $10.10 on Monday after Deutsche upgraded the stock and increased its price target 183%.
Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.
Nasdaq stocks posting largest percentage increases
AP - Fri Aug 15, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod
at Investor's Business Daily - Fri Aug 15, 4:44PM CDT
Big-cap biotech Gilead Sciences (GILD) rose 3.2% to 99.49 on the stock market today, hitting a new all-time high Friday after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.'s...
Why Achillion Pharmaceuticals, Inc. Stock Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 15, 1:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Achillion Pharmaceuticals , a...
